BeOne Medicines (ONCN) AI Stock Analysis

BeOne Medicines

(BMV:ONCN)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

BRUKINSA Market LeadershipBRUKINSA combines leading market position with broad geographic reach and substantial patient adoption. Continued growth across major regions and multiple approved indications can support durable commercial scale, recurring product revenue, and a stronger platform for future oncology launches.

Negative Factors

Intensifying CompetitionA competitive hematology market can pressure BRUKINSA's future growth, prescribing share, and commercial investment requirements. Even without meaningful U.S. impact yet, new combinations and aggressive peer promotion may make it harder to sustain leadership and pricing power.

BeOne Medicines (ONCN) vs. SPDR S&P 500 ETF (SPY)

Market Cap: MXN 39.57B
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): 25.0
Beta (1Y): 0.00
Revenue Growth: 22.04%
EPS Growth: ―
Country: Mexico
Employees: 12,000
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

BeOne Medicines Business Overview & Revenue Model

Company Description

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company’s commercial stage products include BRUKINSA, a small molecule...

BeOne Medicines Earnings Call Summary

Earnings Call Date:Aug 04, 2026(Q2-2026)|% Change Since:0.00%|Next Earnings Date:Nov 05, 2026

Earnings Call SentimentPositive

The call presented a strongly positive commercial and financial picture: robust revenue and EPS growth, raised full‑year guidance, doubled free cash flow, high gross margins, and multiple meaningful regulatory and late‑stage pipeline milestones (MANGROVE result, BEQALZI approval, BTK degrader progress). Headwinds and uncertainties were present but limited relative to the strength described — including a missed uMRD superiority in CELESTIAL‑301 (though PFS remains the primary endpoint), a $60 million tax settlement, increased operating expense guidance to fund pipeline investment, and ongoing competitive dynamics. On balance, the company emphasized durable demand for BRUKINSA, expanding global footprint, and an accelerating late‑stage pipeline, leading to an overall favorable outlook.

Positive Updates

Strong Top-Line Growth

Total revenue of $1.7 billion in Q2 2026, representing 30% year-over-year growth.

Negative Updates

CELESTIAL‑301 uMRD Readout Missed Superiority Bar

In CELESTIAL‑301, the zanubrutinib + sonrotoclax regimen did not reach statistical superiority in uMRD versus the VO regimen; IDMC recommended continuation to the primary PFS endpoint, creating near-term uncertainty around the uMRD comparator result.

Company Guidance

Management raised 2026 guidance, increasing revenue by $300 million to a new range of $6.6–$6.8 billion and boosting GAAP operating income by $250 million to $1.0–$1.1 billion (non‑GAAP operating income now $1.7–$1.8 billion); they expect full‑year gross margin in the high‑80% range and set operating expenses at $4.8–$5.0 billion to fund commercial and pipeline investments (with 2027 OPEX growth expected roughly in line with the past two years). For context from Q2, they reported $1.7 billion revenue, $1.5 billion gross profit (just under 90% gross margin), $1.2 billion operating expenses, $325 million operating income, $237 million net income, GAAP EPS $2.05, adjusted operating income $503 million, adjusted net income $444 million, adjusted diluted EPS $3.84, and free cash flow of $435 million.

BeOne Medicines Risk Analysis

BeOne Medicines disclosed 93 risk factors in its most recent earnings report. BeOne Medicines reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

2 New Risks

1.Below is a summary of the material factors that make an investment in our ADSs listed on Nasdaq, our ordinary shares listed on the Stock Exchange of Hong Kong Limited, and our ordinary shares issued to permitted investors in China and listed and traded on the Science and Technology Innovation Board of the Shanghai Stock Exchange in Renminbi ("RMB Shares") speculative or risky. This summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, are set forth herein and should be carefully considered, together with other information in this Quarterly Report and our other filings with the U.S. Securities and Exchange Commission ("SEC"), before making an investment decision regarding our ADSs, ordinary shares or RMB Shares.Q1, 2026

2.The risk factors denoted with a "*", if any, are newly added or have been materially updated from our Annual Report on Form 10-K for the year ended December 31, 2025 (the "Annual Report").Q1, 2026

BeOne Medicines Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

MX:ONCN against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EXEL	81Outperform	$16.93B	20.11	45.54%	―	9.12%	40.53%
GMAB	71Outperform	$34.91B	45.64	13.58%	―	21.75%	-36.69%
INCY	68Neutral	$24.54B	57.33	7.11%	―	24.88%	-65.67%
SMMT	52Neutral	$12.82B	-14.31	-204.33%	―	―	-11.10%
ZLAB	52Neutral	$2.77B	-12.70	-27.40%	―	5.13%	17.00%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

MX:ONCN and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
MX:ONCN	BeOne Medicines	2530.00	0.00	0.00%
EXEL	Exelixis	69.39	31.33	82.32%
INCY	Incyte	120.39	18.82	18.53%
SMMT	Summit Therapeutics PLC	16.03	-2.19	-12.02%
ZLAB	Zai Lab Ltd	22.07	-4.68	-17.50%
GMAB	Genmab (Otc)	57.06	28.35	98.75%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

BeOne Medicines AI Stock Analysis